… prior bicalutamide (except to prevent flare) or everolimus was allowed. Treatment included
oral bicalutamide 50 mg and oral everolimus … The primary endpoint was the prostate-specific …

… with bicalutamide and everolimus will result in improved efficacy compared to bicalutamide
… of the bicalutamide and everolimus combination in CRPC patients (pts) compared with …

… with bicalutamide and everolimus will result in improved efficacy compared to bicalutamide
… tolerability of the bicalutamide and everolimus combination in CRPC patients compared with …

… No prior bicalutamide (except to prevent flare) or everolimus was allowed. Treatment …
included bicalutamide 50 mg and everolimus 10 mg po, both qd. Primary endpoint was prostate …

… pathway is activated in castrate resistant prostate cancer (CRPC) while inhibition of this …
bicalutamide and the mTOR inhibitor everolimus in CRPC patients compared with bicalutamide …

… with bicalutamide and everolimus will result in improved efficacy compared to bicalutamide
… tolerability of the bicalutamide and everolimus combination in CRPC patients compared with …

… widely implicated in many cancers, including prostate cancer [13]. … prostate cancers and in
up to 70% of advanced cancers, … RAD001 (everolimus) is an orally administered rapamycin …

… tumor growth. There is also preclinical evidence that PI3K pathway inhibition in PTEN-deficient
prostate cancer … .40, 41 Although combining everolimus with bicalutamide showed limited …

… A combination of bicalutamide and everolimus was evaluated in a clinical trial in mCRPC.
Only 2 of the 36 patients enrolled demonstrated a PSA response, and the median PFS was 8.7 …

… Prolonged exposure to bicalutamide also resulted in … bicalutamide and everolimus has very
encouraging efficacy in men with bicalutamide-naïve CRPC, but with substantial everolimus-…